BG Medicine Reports Fourth Quarter and Full Year 2012 Financial Results and Provides 2013 Outlook

[at noodls] – Fourth Quarter and Full Year BGM Galectin-3 Test Sales Grow Significantly Q4 Revenues nearly triple from Q4 2011 Product margins increase 10% from Q4 2011 January 2013$12.8 million public offering supplements … more

View todays social media effects on BGMD

View the latest stocks trending across Twitter. Click to view dashboard

See who BG is hiring next, click here to view